Alkermes plc

Alkermes plc is a biopharmaceutical company that develops pharmaceutical products for unmet medical needs. It has a portfolio of proprietary products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Marketed products include ARISTADA, ARISTADA INITIO, VIVITROL, and LYBALVI. The company has collaboration agreements with Janssen Pharmaceutica companies. Alkermes also offers technology platforms to third parties. Founded in 1987, the company is headquartered in Dublin, Ireland.

Overview

Sector

Pharmaceutical

Target Price

20.5 USD

Current Price

27.0 USD

Potential

-24%

Strengths

Current Price to Earnings Ratio (11.55) is lower than the sector mean (289.29).
Price to book ratio (2.89) is lower than the sector mean (733.70).
EV/EBITDA (9.86) is lower than the sector mean (51.86).
EV/EBIT (10.47) is lower than the sector mean.
Price to free cash flow (10.45) is lower than the sector mean.
Strong EBITDA Margin of 31.77%.

Weaknesses

With a depreciation Potential of -21.65%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.

Key Financial Data

Indicator	Value
PER	11.9
EV/EBITDA	10.1
Price/Free Cash Flow'	10.8
ROIC	18.3%
Net Debt/EBITDA	1.3